Caplight Directory>Companies>Braveheart Bio-preview>Braveheart


Braveheart Bio

Braveheart Bio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://braveheart.bio

Last Round

Series A

Nov 5, 2025

Total Funding Raised

$185M

Company Overview

Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B2C

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

hypertrophic cardiomyopathyHCMcardiac myosin inhibitorsmall-molecule therapeuticclinical-stage biotechbiopharmacardiovascular therapeuticsdrug developmentlate-stage clinical trialsoral therapeuticin-licensingheart disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Braveheart Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Braveheart Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ANov 5, 2025
View all Funding Rounds

Braveheart Bio Investors

Notable investors and investment history

InvestorRounds
Andreessen HorowitzSeries A
Enavate SciencesSeries A
ForbionSeries A
OrbiMedSeries A
Frazier Life SciencesSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    Lee Bockus joins as Senior Medical Director.

  • Mar 31, 2026

    Peter Riebling joins as Senior Director, Medical Writing.

View all signals

Braveheart Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Braveheart Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Braveheart Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Year Founded2024
Last FundingNov 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.